Please Wait
Applying Filters...
Digital Content 
NEWS #PharmaBuzz
24 Sep 2024
// GLOBENEWSWIRE
https://www.globenewswire.com/news-release/2024/09/24/2952105/37414/en/First-Patient-Enrolled-in-Phase-I-Program-in-STK11-Mutant-Non-Small-Cell-Lung-Cancer-at-Moffitt-Cancer-Center.html
06 May 2024
// GLOBENEWSWIRE
https://www.globenewswire.com/news-release/2024/05/06/2875759/37414/en/Panbela-Announces-Issuance-of-New-Patent-in-the-US-and-Canada-Patent-is-for-Claims-of-a-Fixed-Dose-Combination-of-Eflornithine-and-Sulindac.html
30 Apr 2024
// GLOBENEWSWIRE
https://www.globenewswire.com/news-release/2024/04/30/2872189/37414/en/Acceptance-of-Eflornithine-DFMO-Abstract-for-Oral-Presentation-at-Digestive-Disease-Week.html
15 Apr 2024
// PR NEWSWIRE
https://www.prnewswire.com/news-releases/norgine-bv-submits-marketing-authorisation-application-via-project-orbis-for-eflornithine-difluoromethylornithine-dfmo-in-high-risk-neuroblastoma-302116815.html
18 Dec 2023
// GLOBENEWSWIRE
https://www.globenewswire.com//news-release/2023/12/18/2797829/37414/en/Panbela-Therapeutics-Announces-US-WorldMeds-NDA-Approval-for-Eflornithine-DFMO-in-Pediatric-Neuroblastoma.html
https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-eflornithine-adult-and-pediatric-patients-high-risk-neuroblastoma?utm_medium=email&utm_source=govdelivery
LOOKING FOR A SUPPLIER?
Market Place
Share